Insulin sensitiser drugs

Insulin resistance is the predominant early pathological defect in Type 2 d iabetes. As well as being a risk factor for the development of Type 2 diabe tes, insulin resistance is also associated with increased cardiovascular ri sk and other metabolic disturbances including visceral adiposity, hyperinsu linaemia, impaired glucose tolerance, hypertension and dyslipidaemia [1-4]. The newest approach to oral antidiabetic therapy is to target improvements in insulin sensitivity at muscle, adipose tissue and hepatic level. This r esults in improvements in glycaemic control and other features of the insul in resistance syndrome, with potential long-term benefits in preventing/del aying the onset of diabetic complications and macrovascular disease.